Millendo Therapeutics Appoints New Independent Board Member and Names Chairperson of the Board

Millendo Therapeutics, Inc., a company developing novel therapies for endocrine diseases caused by hormone dysregulation, announced the appointment of James Hindman as an independent board member and chairperson of its audit committee. In addition, Millendo has appointed current board member and Partner of New Enterprise Associates, Inc., Carol Gallagher, Pharm.D., as Chairperson of the Board.

Hindman most recently served as Executive Vice President of Finance and Business Development and Chief Financial Officer at Allergan, Inc., where, under his leadership, the company achieved its most robust financial performance in Allergan’s 64-year history. 

Read the full press release here.